Abstract:Innate immune responses recognizing pathogen associated molecular patterns play important roles in adaptive immunity. As such, ligands which mimic the conserved products of microbial and activate innate immunity are widely used as adjuvants for vaccines. Synthetic single strand oligodeoxynucleotides (ODNs) containing unmethylated cytosine-guanine (CpG) motifs which bind Toll-like receptor 9 (TLR9) are powerful molecular adjuvants, potentiating both humoral and cellular responses. However, CpG ODN's in vitro potency has not been translated to in vivo settings primarily due to issues associated with delivery and toxicity. A major challenge in clinical application of CpG ODN is the efficient delivery to lymph nodes, the anatomic sites where all the immune responses are initiated. Targeting CpG to the key antigen presenting cells (APC) is essential for its application as a vaccine adjuvant, as it not only enhances CpG's efficacy, but also greatly reduces the systemic toxicity. We recently discovered an "albumin-hitchhiking" approach by which CpG ODNs were conjugated to a lipophilic lipid tail and follow subcutaneous injection, accumulated in lymph nodes by binding and transporting with endogenous albumin. This molecular approach targets CpG to antigen presenting cells in the draining lymph nodes via an endogenous albumin-mediated mechanism and simultaneously improves both the efficacy and safety of CpG as a vaccine adjuvant. Since CpG ODNs can be divided into structurally distinct classes, and each class of CpG ODN activates different types of immune cells and triggers different types of immunostimulatory activities, it is important to thoroughly evaluate the efficacy of this "albumin-hitchhiking" strategy in each class of CpG. Here we compare the immunostimulatory activities of three classes of lipid conjugated CpG ODNs in vitro and in vivo. Three representative sequences of lipid modified CpG ODNs were synthesized and their stimulatory effects as a vaccine adjuvant were evaluated. Our results showed that in vitro, lipid modified class A CpG exhibited enhanced stimulatory activities toward TLR transfected reporter cells or bone-marrow derived dendritic cells, whereas lipid-modification of class B or C CpG reduces the activation of TLR9 by 2-3 fold, as compared with unmodified class B and class C CpG, respectively. However, in vivo coadministration of ovalbumin (OVA) protein antigen mixed with lipid-conjugated class B or C CpG ODNs, but not class A CpGs induced dramatically increased OVA-specific humoral and cytotoxic CD8+ T cells responses compared with OVA mixed with unmodified CpGs. Further, lipid-modification greatly reduces the toxicity associated with CpG by minimizing the systemic dissemination. Taken together, these results demonstrated that amphiphilic modification of three classes of CpG motifs differentially affected and modulated the immunostimulatory activities in vitro and in vivo. Our study highlights the importance of in vivo lymph node targeting of CpG ODNs in fulfilling their use as vaccine adjuvants, providing implications for the rational design of molecular adjuvant for subunit vaccines.

Non-Methylated Cpg Motif Packaged into Fusogenic Liposomes Enhance Antigen-Specific Immunity in Mice

Enhanced Immunostimulatory Activity of a Cytosine-Phosphate-Guanosine Immunomodulator by the Assembly of Polymer DNA Wires and Spheres

Augmentation of Antigen-Specific Immune Responses Using DNA-fusogenic Liposome Vaccine.

Enhancing Immunogenicity by CpG DNA.

Combinations of Various CpG Motifs Cloned into Plasmid Backbone Modulate and Enhance Protective Immunity of Viral Replicon DNA Anthrax Vaccines

Double-stranded Phosphodiester Cytosine-Guanine Oligodeoxynucleotide Complexed with Calcium Phosphate As a Potent Vaccine Adjuvant for Activating Cellular and Th1-type Humoral Immunities

Effects of Multiple Copies of CpG on DNA Vaccination.

Plasmid DNA Containing Multiple CpG Motifs Triggers a Strong Immune Response to Hepatitis B Surface Antigen when Combined with Incomplete Freund’s Adjuvant but Not Aluminum Hydroxide

Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides

Adjuvant Effect of CpG DNA Recombinant Plasmid to Antigen of FMDV in Vivo

Enhancement of HIV-1 DNA vaccine immunogenicity with CpG adjuvant

Three Types of Humancpg Motifs Differentially Modulate and Augment Immunogenicity of Nonviral and Viral Replicondna Vaccines As Built‐in Adjuvants

Immunostimulatory Properties of Dynamic Oligonucleotide Micelles (53.9)

Self-Assembled DNA Immunonanoflowers As Multivalent CpG Nanoagents

Enhanced Immunogenicity of Foot and Mouth Disease DNA Vaccine Delivered by PLGA Nanoparticles Combined with Cytokine Adjuvants

Enhancement of Immune Response of Bioconjugate Nanovaccine by Loading of CpG through Click Chemistry

Enhanced Efficacy of DNA Vaccination Against Botulinum Neurotoxin Serotype A by Co-Administration of Plasmids Encoding DC-stimulating Flt3L and MIP-3α Cytokines.

A Comparative Study of the Antigen‐specific Immune Response Induced by Co‐delivery of CpG ODN and Antigen Using Fusion Molecules or Biodegradable Microparticles**xue‐qing Zhang and Christopher E. Dahle Contributed Equally to This Work.

Lipid Nanoparticle Delivery Alters The Adjuvanticity of The TLR9 Agonist Cpg by Innate Immune Activation in Lymphoid Tissue

Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo

Cytosine-phosphate-guanine oligodeoxynucleotides containing GACGTT motifs enhance the immune responses elicited by keyhole limpet hemocyanin antigen in dairy cattle